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ABSTRACTS
Gregory L. Moneta, MD, Section EditorAspirin and Extended-Release Dipyridamole vs. Clopidogrel for Recur-
rent Stroke
Sacco RL, Diener H-C, Yusuf S, and the PRoFESS Study Group. New Engl
J Med 2008;359:1238-51.
Conclusion:Rates of recurrent stroke are similar in patients with stroke
treated with aspirin and extended release dipyridamole vs those treated with
clopidogrel.
Summary: Surviving patients with ischemic stroke are at risk for
recurrent stroke. Multiple trials have proven the efficacy of antiplatelet
agents in prevention of recurrent stroke after non-cardioembolic stroke.
Which particular antiplatelet therapy may work best in the prevention of
recurrent stroke is unknown. This trial studied the relative efficacy and safety
of aspirin plus extended-release dipyridamole (ERDP) for prevention of
recurrent stroke compared with patients treated with clopidogrel. This is a
double-blind, two-by-two factorial trial. Patients were randomly assigned to
receive 75 mg of aspirin plus 200 mg of ERDP twice daily, or to receive 75
mg of clopidogrel daily. The primary outcome was first recurrence of stroke.
The secondary end point was a composite of myocardial infarction, stroke, or
death from cardiovascular cause. The trial was designed as a noninferiority
trial with sequential statistic testing of noninferiority, followed by superiority
testing. A total of 20,332 patients were followed up worldwide, with a mean
follow-up of 2.5 years. In patients receiving aspirin and ERDP, recurrent
stroke occurred in 916 (9%). In patients receiving clopidogrel, recurrent
stroke occurred in 898 (8.8%), with a hazard ratio (HR) of 1.01 (95%
confidence interval [CI], 0.92-1.11). The secondary composite outcome
occurred in 13.1% of patients in each group (HR for aspirin/ERDP, 0.99;
95% CI, 0.92-1.07). Patients treated with aspirin/ERDP had 4.1% (n 
419) major hemorrhagic events compared with 3.6% (n  365) in patients
treated with clopidogrel (HR, 1.15; 95% CI, 1.00-1.32) and had more
intracranial hemorrhage (HR, 1.42; 95% CI, 1.11-1.83). The net risk of a
major hemorrhagic event or recurrent stroke was similar in the two groups,
11.7% in the aspirin/ERDP group vs 11.4% in the clopidogrel group (HR,
1.03; 95% CI, 1.95-1.11).
Comments: The study indicates no significant difference between the
use of aspirin/ERDP vs clopidogrel in preventing recurrent stroke. This was
a huge study with high patient numbers and international representation
from 35 countries or regions. The results of the study, therefore, should be
generalizable worldwide. Although the study failed to identify a superior
treatment to prevent recurrent stroke, we now know the expected risk of
recurrent stroke in patients treated according to the study protocol. The
study has also provided us safety and efficacy data for physicians concerning
individual treatment decisions for their patients with ischemic stroke.
Effects of Age and Symptom Status on Silent Ischemic Lesions after
Carotid Stenting With and Without the Use of Distal Filter Devices
Kastrup A, Groschel K, Magele T, et al. Am J Neuroradiol 2008;29:608-12.
Conclusion: Distal filter devices can reduce the incidence of new
diffusion-weighted imaging (DWI) lesions associated with carotid stenting,
but benefit may not necessarily pertain to older and asymptomatic patients.
Summary: Routine use of distal filter devices during carotid angio-
plasty and stenting (CAS) remains controversial. The authors sought to
determine if certain subgroups of patients might benefit compared with
others with the use of filter devices. They used new lesions shown onDWI as
surrogate markers for stroke. Sixty patients underwent CAS with a distal
filtration device and 175 without a distal protective device. All patients were
studied with DWI imaging immediately before and after CAS. Patients were
stratified according to age and symptom status. New ipsilateral DWI lesions
were frequent after CAS in patients with and without neural protective
devices; however, there appeared to be fewer lesions in patients undergoing
protected (52%) vs unprotected CAS (68%). In symptomatic patients, there
was a 56% prevalence of new DWI lesions with protective devices vs 74% in
those without the use of protective devices. In patients aged 75 years,
incidence of DWI lesions was 46% with protective devices vs 67% without
protective devices (all P  .05). In asymptomatic patients and in patients
aged 75 years, the proportion of patients with new lesions and the total
number of new lesions were not significantly different between those treated
with protected and unprotected CAS. For the entire study population, the
incidence of any stroke or death ’30 days was not significantly different
between patients treated with and without neural protection (8.8% vs 5.1%;
P .4). Neurologic complication rates30 days also were not significantly
different among younger, older, symptomatic, or asymptomatic patients
treated with and without protective devices.
272Comment: This is a retrospective and nonrandomized study. The
nature of the study design does not truly permit conclusions about the utility
of neuroprotective devices in symptomatic vs asymptomatic and younger vs
older patients. Nevertheless, the high prevalence of new DWI lesions in
patients treated with and without neuroprotective devices and the lack of
dramatic effects of neuroprotective devices on neurologic events associated
with CASmakes one wonder about the efficacy of neuroprotective devices or
the mechanism of new DWI lesions after CAS, or both.
Ten-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Holman RR, Paul SK, Bethel A, et al. N Engl J Med 2008;359:1577-89.
Conclusion: With 10 years of follow-up, patients with newly diag-
nosed type 2 diabetes initially treated with intensive glucose reducing
therapy have lower long-term risk of myocardial infarction and death from
any cause.
Summary: The United Kingdom Prospective Diabetes Study (UKPDS)
found patients with newly diagnosed type 2 diabetes who received intensive
glucose therapy had a lower risk ofmicrovascular complications than patients
who received only conventional dietary therapy. This study sought to
determine whether improved glucose control persisted in the UKPDS
patients and whether such therapy affected macrovascular outcomes in the
long term.
The original UKPDS study randomized 5102 patients with newly
diagnosed type 2 diabetes. Of these, 4209 were randomly assigned to receive
dietary restriction (conventional therapy) or intensive therapy using sulfo-
nylurea or insulin, or, in overweight patients, metformin. UKPDS clinics
were held for 5 years after the trial ended, and 3277 patients were asked to
attend. No attempts were made to maintain previously assigned therapies.
Patients unable to attend the clinics were queried with annual question-
naires, and questionnaires were used for all patients in years 6 to 10. Data was
analyzed on an intention-to-treat basis with respect to the original random-
ization categories.
Differences in glycated hemoglobin levels among the groups were lost
after the first year of completion of the trial. However, the relative reduction
in risk persisted at 10 years in the sulfonylurea/insulin group for any
diabetes-related end point (9%, P  .04) and microvascular disease (24%,
P  .001). Risk reductions were also found for myocardial infarction (15%,
P  .01) and death from any cause (13%, P  .007). Patients treated with
metformin also had persistent risk reduction for any diabetes-related end
point (21%, P .01), myocardial infarction (33%, P .005), and death from
any cause (27%, P  .002).
Comment: This study, with more than 66,000 person-years of follow-
up, indicates benefit of intensive blood glucose control in patients with
newly diagnosed type 2 diabetes that are followed for 10 years after cessation
of randomization intervention. This occurred despite the fact that early trial
differences in glycated hemoglobin levels between groups were lost over
time; a so-called legacy effect. At first glance this trial would appear to be in
direct opposition to the ADVANCE and ACCORD trials, which appeared in
the New England Journal of Medicine also in 2008 (N Engl J Med 2008;
358:2560-72, and N Engl J Med 2008;358:2545-59). However, the cur-
rent study, and ADVANCE and ACCORD, studied different groups of
patients. The UKPDS group used only newly diagnosed type 2 diabetic
patients. The ADVANCE and ACCORD trials involved higher-risk patients
aged 8 to 12 years older than those in the UKPDS trial and patients who had
been treated for diabetes for 8 to 10 years. A history of macrovascular disease
was also present in about 33% of the patients in ADVANCE and ACCORD
but in only 7.5% of the patients in the UKPDS. Perhaps the most intriguing
result of this study is the sustained legacy effect of early-on intensive glucose
control in patients with newly diagnosed type 2 diabetes. Early aggressive
treatment appears beneficial, suggesting there may be a move away from the
traditional paradigm of initially trying diet alone as therapy for newly
diagnosed type 2 diabetes.
Residual Vein Thrombosis to Establish Duration of Anticoagulation
After a First Episode of Deep Vein Thrombosis: The Duration of
Anticoagulation Based on Compression UltraSonography (DACUS)
Study
Siragusa S, Malato A, Anastasio R, et al. Blood 2008;112:511-5.
Conclusion: Absence of residual venous thrombus (RVT) after a first
episode of deep venous thrombosis (DVT) identifies a group of patients at
very low risk for recurrent DVT after stopping oral anticoagulation therapy.
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 1 Abstracts 273Summary: RVT after DVT may be a prothrombotic state. The pres-
ence or absence of RVT after treatment for DVT is therefore potentially
useful for evaluating optimal duration of oral anticoagulant treatment
(OAT). In this study, patients with the first episode of DVT and treated with
OAT for 3 months were managed with respect to RVT findings. After 3
months of OAT, those with RVT were randomized to either stop or
continue anticoagulants for 9 additional months. In those without RVT,
OAT was stopped. Outcome events were recurrent DVT or major bleeding,
or both. There were 258 patients. RVT was detected in 180 (69.8%). In
those with RVT, recurrent events occurred in 27.2% of those (25 of 92) who
discontinued OAT, and recurrent events occurred in 19.3% of those (17 of
88) who continued OAT. The adjusted hazard ratio was 1.58 (95% confi-
dence interval [CI], 0.85-2.93; P .145). In the 78 patients without RVT,
only one had recurrent VTE. Adjusted hazard ratio of patients with RVT vs
those without RVT was 24.9 (95% CI, 3.4-183.6; P  .002). One major
bleeding event (1.1%) occurred in patients who stopped OAT (0.53%
person-years), and two bleeding events (2.3%) occurred in those who
continued OAT (1.1% person-years).
Comment: The results suggest assessment for RVT is useful in evalu-
ating risk of DVT recurrence after stopping OAT after a first episode of
DVT. This trial included patients with both provoked and idiopathic DVT.
Many of the patients without RVT after OAT had had an initially provoked
DVT. However, no differences in outcomes were noted when patients with
provoked DVT were compared with those with idiopathic DVT. In patients
with RVT, recurrence is high even if the index DVT was provoked. This trial
should help identify patients with initial episode of DVT who are very
adequately treated with a short period of anticoagulation.
Chronic Kidney Disease Increases Risk for Venous Thromboembolism
Wattanakit K, Cushrnan M, Stehman-Breen C, et al. J Am Soc Nephrol
2008;19:135-40.
Conclusion: Patients with advanced chronic kidney disease (CKD) are
at increased risk for incident venous thromboembolism (VTE).
Summary: CKD is known to be associated with increased risk of
morbidity and mortality from cardiovascular disease. This study sought to
evaluate in a community-based population the risk of VTE in CKD patients
who were not dependent on dialysis. The authors used data from the
Longitudinal Investigation of Thromboembolism Etiology (LITE) study.
This study used established cohorts from the Atherosclerosis Risk in Com-
munities (ARIC) study and the Cardiovascular Health Study (CHS). Alto-
gether, 19,073 middle-aged and elderly adults were categorized on the basis
of estimated glomerular filtration rate (GFR) and cystatin C concentration.
Cystatin C levels were only available in patients from the CHS study. The
patients were divided into quartiles by estimated GFR and cystatin C.
During a mean follow-up of 11.8 years, VTE developed in 413
participants. The relative risk of VTE in patients with mildly decreased
renal function compared with those with normal renal function was 1.28
(95% confidence interval [CI], 1.02-1.59). For those with stage III or IV
CKD, the relative risk for VTE was 2.09 (95% CI, 1.47-2.96). This was
with adjustment for age, gender, race, and center. An increased risk of
VTE was still observed in participants with stage III/IV CKD after
further adjustment for cardiovascular disease risk factors (relative risk,
1.17; 95% CI, 1.18-2.49). There was no significant association between
cystatin C and VTE.
Comment: This is the first study demonstrating the association be-
tween mild to moderate decreased kidney function and VTE in the general
population. It is important to remember that estimation of renal function in
this study was based on a single measurement of serum creatinine that
occurred at an average of 11.8 years before the incident VTE events. It is
unclear whether changes in kidney function during this almost 12-year
interval could have resulted in systematic misclassification of CKD status at
the time of the VTE event. Therefore, the data should be regarded as
suggestive, but not definitive, that patients with mild to moderate CKD are
at increased risk for VTE.
Incident Physical Disability in People with Lower Extremity Peripheral
Arterial Disease: The Role of Cardiovascular Disease
Brach JS, Solomon C, Naydeck BL and the Cardiovascular Health Study
Research Group. J Am Geriatr Soc 2008;56:1037-44.
Conclusion: A low ankle-brachial index (ABI) serves as a marker of
future disability risk.
Summary: The authors point out that an association exists between
peripheral arterial disease (PAD) and function in people with clinically
diagnosed PAD. The stimulus for this study is that it is actually unknown
whether nondisabled community-dwelling older adults with low ABIs are at
risk for development of new disability. In this study the authors evaluated the
risk of incident physical disability and declining gait speed during a 6-year
follow-up and associated this with low ABI in older adults. This was an
observational cohort study conducted in Forsyth County, North Carolina;
Sacramento California, Washington County, Maryland; and AlleghenyCounty, Pennsylvania. There were 4705 older adults (58% women) partic-
ipating in this study through the CardiovascularHealth Study; of these, 7.6%
were African American.
The ABI was measured at a baseline examination in 1992 or 1993.
Baseline self-reported mobility, activities of daily living (ADL), and instru-
mental ADL, disability, and gait speed were recorded at baseline and at
subsequent 1-year intervals for 6 years of follow-up. Mobility disability was
defined as difficulty of any sort in walking one-half mile. Disability with ADL
was described as difficulty with any 11 prespecified tasks. Patients with
mobility disabilities or disabilities involving ADL at baseline were excluded
from respective incident disability analysis.
Lower baseline ABI values were associated with increased risk of late
incident mobility disability and ADL disability. Associations for mobility
disability were partially explained by cardiovascular disease, diabetes melli-
tus, and interim cardiovascular disease events. New ADL disability was
partially explained by diabetes mellitus. Subjects with an ABI 0.9 had an
average mean decreasing gait speed of 0.02 m/s per year, a decline of 0.12
m/s during 6 years of follow-up. This was partly explained by prevalent
cardiovascular disease, but interim cardiovascular events did not contribute
to this further.
Comment: This study has some weaknesses in that disability in the
subjects is based primarily on self-reporting. In addition, most of the patients
in this study had mild peripheral arterial disease, and the results are likely not
generalizable to patients with more severe decreases in their ABI. Neverthe-
less, it does appear that asymptomatic PAD, although well recognized as a
risk for death from cardiovascular disease, is also a significant risk factor for
future disability in asymptomatic patients.
Aortic Atherosclerosis, Hypercoagulability, and Stroke: The APRIS
(Aortic Plaque and Risk of Ischemic Stroke) Study
Tullio MR, Homma S, Jin Z. J Am Coll Cardiol 2008;52:855-61.
Conclusion: In patients with acute ischemic stroke, large proximal
aortic plaques are associated with hypercoagulability. The combination of
large proximal aortic plaques and hypercoagulability results in an increased
risk of recurrent stroke and death.
Summary: Large plaques in the proximal portion of the aorta are
associated with an increased risk of ischemic stroke. Plaque thickness is
related to stroke risk, and a 4-mm thick plaque is considered clinically
relevant for risk stratification. Ulcerations and mobile components of these
plaques also contribute to embolic risk. It is suggested that superimposed
thrombotic material on the aortic plaque may contribute to its thickness and
the enhanced stroke potential of the plaque. The authors sought to deter-
mine whether a relationship existed between the aortic plaques and hyper-
coagulability that perhaps could predispose to thrombus formation and
stroke risk. Transesophageal echocardiography was performed in 255 pa-
tients with a first ischemic stroke and in 209 control subjects matched by age,
gender, and race/ethnicity. A case–control design was used to assess the
association between arch plaques and hypercoagulability and its effect on
stroke risk. Patients were followed up prospectively to assess for recurrent
stroke and death.
Arch plaques 4 mm were associated with increased stroke risk (ad-
justed odds ratio [OR], 2.4; 95% confidence interval [CI], 1.3-4.6). This
relationship was more pronounced when superimposed thrombus or ulcer-
ations were present (adjusted OR, 3.3; 95% CI, 1.4-to 8.2). Prothrombin
fragment F1.2 was associated with large plaques in patients with acute
ischemic stroke but not in control subjects (P  .02). Mean follow-up was
55.1  37.2 months. During follow-up, stroke patients with large plaques
and F1.2 that exceeded the median value had an increased risk of recurrent
stroke and death compared with those with large plaques but lower F1.2
levels (230 events/1000 patient-years vs 85 events/1000 patient-years;
P  .05).
Comments: This study draws an association between activation of
coagulation parameters and risk of stroke in patients with aortic arch plaques.
Prothrombin fragment F1.2 is a byproduct of the conversion of prothrom-
bin to thrombin and is an excellent indicator of thrombin generation. The
results of the study suggest an overall association between hypercoagulabil-
ity, aortic plaque thickness, and ischemic stroke. The best treatment for
emboli likely originating from an aortic plaque is unknown. Anticoagulation
agents are usually prescribed for most thrombi, whereas antiplatelet agents
are often used for plaques 4 mm in thickness but not without superim-
posed mobile thrombus. The results here suggest that prothrombin frag-
ment F1.2 levels should be assessed in patients with large nonmobile aortic
plaques and ischemic strokes, assessed at least for prognostic reasons. Future
trials will be necessary to evaluate whether systemic anticoagulation may
reduce the risk of subsequent stroke in patients with elevated fragment F1.2
levels and large proximal aortic plaques.
Predictors and Outcomes of a Perioperative Myocardial Infarction
Following Elective Vascular Surgery in Patients with Documented
Coronary Artery Disease: Results of the CARP Trial
McFalls EO, Ward HB, Moritz TE, et al. Eur Heart J 2008;29:394-401.
